株探米国株
日本語 英語
エドガーで原本を確認する
0001606757false00016067572024-05-072024-05-07

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)   May 7, 2024
keilogoonelinecolorcmyk2revi.jpg
KIMBALL ELECTRONICS, INC.
________________________________________________________________________________________________________
(Exact name of registrant as specified in its charter)
     
Indiana 001-36454 35-2047713
(State or other jurisdiction of (Commission File (IRS Employer Identification No.)
incorporation) Number)  
     
1205 Kimball Boulevard, Jasper, Indiana
  47546
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code   (812) 634-4000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class Trading Symbol Name of each exchange on which registered
Common Stock, no par value KE The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.02 Results of Operations and Financial Condition
On May 7, 2024, the Company issued an earnings release for the third quarter ended March 31, 2024. The earnings release is attached as Exhibit 99.1.
The information in Item 2.02 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, except as shall otherwise be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit  
Number Description
99.1
104 Cover Page Interactive Data File (formatted in Inline XBRL)

2


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
   
  KIMBALL ELECTRONICS, INC.
   
By: /s/ Jana T. Croom
  JANA T. CROOM
Chief Financial Officer
Date: May 7, 2024

3
EX-99.1 2 exhibit9918k03312024q310q.htm KIMBALL ELECTRONICS, INC. EXHIBIT 99.1 Document

Exhibit 99.1
KIMBALL ELECTRONICS REPORTS Q3 RESULTS; COMPANY ANNOUNCES RENEWED STRATEGIC FOCUS, INCLUDING EXPECTED DIVESTITURE OF THE AUTOMATION, TEST & MEASUREMENT BUSINESS


JASPER, Ind., May 7, 2024 -- (BUSINESS WIRE) -- Kimball Electronics, Inc. (Nasdaq: KE) today announced financial results for the third quarter of fiscal 2024 with net sales totaling $425.0 million and a net loss of $6.1 million, or $0.24 per share. This result includes the impairment of the Automation, Test & Measurement business, which the Company expects to divest, along with restructuring expense, partially offset by the recovery of a legal settlement. A detailed reconciliation is provided later in this release.

•Excluding these items, adjusted net income in the third quarter of fiscal 2024 totaled $8.4 million, or $0.34 per diluted share, and adjusted operating income equaled $17.0 million, or 4.0% of net sales.
•Cash flow from operating activities in the quarter was $42.6 million driven by inventory reductions.
•Company sharpens strategic focus on EMS operations and aligns cost structure to short-term demand trends.
•Guidance for adjusted operating income in fiscal 2024 reiterated, while the estimate for net sales was updated, in response to the challenging operating environment, and capital expenditures strategically reduced.
•Resumption of share repurchases approved by the Board of Directors.
Three Months Ended Nine Months Ended
March 31, March 31,
(Amounts in Thousands, except EPS) 2024 2023 2024 2023
Net Sales $ 425,036  $ 484,703  $ 1,284,352  $ 1,327,288 
Operating Income $ (6,431) $ 25,220  $ 29,669  $ 56,280 
Adjusted Operating Income (non-GAAP) (1)
$ 16,960  $ 25,573  $ 53,367  $ 56,738 
Operating Income % (1.5) % 5.2  % 2.3  % 4.2  %
Adjusted Operating Income (non-GAAP) % 4.0  % 5.3  % 4.2  % 4.3  %
Net Income (Loss)
$ (6,076) $ 16,400  $ 12,968  $ 36,629 
Adjusted Net Income (non-GAAP) (1)
$ 8,441  $ 16,400  $ 27,485  $ 36,908 
Diluted EPS $ (0.24) $ 0.65  $ 0.51  $ 1.46 
Adjusted Diluted EPS (non-GAAP) (1)
$ 0.34  $ 0.65  $ 1.09  $ 1.47 
(1) A reconciliation of GAAP and non-GAAP financial measures is included below.

Commenting on today’s announcement, Richard D. Phillips, Chief Executive Officer, stated, “As we anticipated, the operating environment has remained challenged for the EMS industry, and our sales in the third quarter declined as expected. During this period of end market softness, we have focused on ‘controlling what we can control,’ proactively aligning our cost structure with short-term demand trends, maintaining competitiveness with stable operating margins, and focusing on working capital improvements.”

Mr. Phillips continued, “We’re taking meaningful steps to sharpen our strategic focus and further position the Company for profitable growth, and stronger performance moving forward. With the expected divestiture of the Automation, Test & Measurement business, our team can increase focus and support on our core EMS operations. While we suspect the macro headwinds will persist in fiscal 2025, we’re continuing to make investments in long-term growth opportunities supported by a robust funnel for new business in the next 18-24 months, while deploying a capital allocation strategy that balances growth, lasting customer relationships, and returning cash to Share Owners with opportunistic share repurchases.”



The Company ended the third quarter of fiscal 2024 with cash and cash equivalents of $65.2 million and borrowings outstanding on credit facilities of $319.6 million, including $235.0 million classified as long term, and $117.4 million of borrowing capacity available. Capital expenditures were $13.4 million in Q3.


Net Sales by Vertical Market for Q3 Fiscal 2024:
Three Months Ended Nine Months Ended
March 31, March 31,
(Amounts in Millions) 2024 * 2023 * Percent Change 2024 * 2023 * Percent Change
Automotive (1)
$ 202.0  47  % $ 221.9  46  % (9) % $ 614.7  48  % $ 615.3  46  % —  %
Medical (1)
113.0  27  % 135.5  28  % (17) % 323.5  25  % 377.1  29  % (14) %
Industrial (1)
110.0  26  % 127.3  26  % (14) % 346.2  27  % 334.9  25  % %
    Total Net Sales $ 425.0  $ 484.7  (12) % $ 1,284.4  $ 1,327.3  (3) %
*As a percent of Total Net Sales
(1) Beginning in fiscal year 2024, miscellaneous sales previously reported in Other are now reported in the respective three end market verticals; all prior periods have been recast to conform to current period presentation
–Automotive includes electronic power steering, body controls, automated driver assist systems, and electronic braking systems
–Medical includes sleep therapy and respiratory care, image guided therapy, in vitro diagnostics, drug delivery, AED, and patient monitoring
–Industrial includes climate controls, automation controls, optical inspection, and public safety

Guidance for Fiscal Year 2024
The Company reiterated its guidance for adjusted operating income in fiscal year 2024 of 4.2% to 4.6% of net sales. In response to the current economic environment, net sales are now expected to decline 4% to 6%, compared to the previous estimate of a 2% to 4% decrease. Capital expenditures are estimated to be in the range of $55 to $60 million, compared to the previous guidance of $70 to $80 million.




Forward-Looking Statements
Certain statements contained within this release are considered forward-looking, including our fiscal year 2024 guidance, under the Private Securities Litigation Reform Act of 1995. The statements may be identified by the use of words such as “expect,” “should,” “goal,” “predict,” “will,” “future,” “optimistic,” “confident,” and “believe.” Undue reliance should not be placed on these forward-looking statements. These statements are based on current expectations of future events and thus are inherently subject to uncertainty. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. These forward-looking statements are subject to risks and uncertainties including, without limitation, global economic conditions, geopolitical environment and conflicts such as the war in Ukraine, global health emergencies, availability or cost of raw materials and components, foreign exchange rate fluctuations, and our ability to convert new business opportunities into customers and revenue. Additional cautionary statements regarding other risk factors that could have an effect on the future performance of the company are contained in its Annual Report on Form 10-K for the year ended June 30, 2023.

Non-GAAP Financial Measures
This press release contains non-GAAP financial measures. The non-GAAP financial measures contained herein include constant currency growth, adjusted operating income, adjusted net income, adjusted diluted EPS, and ROIC. Reconciliations of the reported GAAP numbers to these non-GAAP financial measures are included in the Reconciliation of Non-GAAP Financial Measures section below. Management believes these measures are useful and allow investors to meaningfully trend, analyze, and benchmark the performance of the company’s core operations. The company’s non-GAAP financial measures are not necessarily comparable to non-GAAP information used by other companies.

About Kimball Electronics, Inc.
Kimball Electronics is a multifaceted manufacturing solutions provider of electronics and diversified contract manufacturing services to customers around the world. From our operations in the United States, China, India, Japan, Mexico, Poland, Romania, Thailand, and Vietnam, our teams are proud to provide manufacturing services for a variety of industries. Recognized for a reputation of excellence, we are committed to a high-performance culture that values personal and organizational commitment to quality, reliability, value, speed, and ethical behavior. Kimball Electronics, Inc. (Nasdaq: KE) is headquartered in Jasper, Indiana.
To learn more about Kimball Electronics, visit: www.kimballelectronics.com.
Conference Call / Webcast
Date: May 8, 2024
Time: 10:00 AM Eastern Time
Live Webcast: investors.kimballelectronics.com/events-and-presentations/events
Dial-In #:
404-975-4839 (other locations - 833-470-1428)
Conference ID:
889032
For those unable to participate in the live webcast, the call will be archived at investors.kimballelectronics.com.
Lasting relationships. Global success.



Financial highlights for the third quarter and year-to-date period ended March 31, 2024 are as follows:
Condensed Consolidated Statements of Income
(Unaudited) Three Months Ended
(Amounts in Thousands, except Per Share Data) March 31, 2024 March 31, 2023
Net Sales $ 425,036  100.0  % $ 484,703  100.0  %
Cost of Sales 391,492  92.1  % 441,731  91.1  %
Gross Profit 33,544  7.9  % 42,972  8.9  %
Selling and Administrative Expenses 16,861  3.9  % 17,752  3.7  %
Other General Expense (Income) (892) (0.2) % —  —  %
Restructuring Expense 1,622  0.4  % —  —  %
Goodwill Impairment 5,820  1.4  % —  —  %
Asset Impairment 16,564  3.9  % —  —  %
Operating Income (Loss)
(6,431) (1.5) % 25,220  5.2  %
Interest Income 83  —  % 45  —  %
Interest Expense (5,875) (1.4) % (4,822) (1.0) %
Non-Operating Income (Expense), net (530) (0.1) % 1,433  0.3  %
Other Income (Expense), net (6,322) (1.5) % (3,344) (0.7) %
Income Before Taxes on Income (12,753) (3.0) % 21,876  4.5  %
Provision for Income Taxes (6,677) (1.6) % 5,476  1.1  %
Net Income (Loss)
$ (6,076) (1.4) % $ 16,400  3.4  %
Earnings Per Share of Common Stock:
Basic $ (0.24) $ 0.66 
Diluted $ (0.24) $ 0.65 
Average Number of Shares Outstanding:
     Basic 25,118  24,898 
     Diluted 25,118  25,067 
(Unaudited) Nine Months Ended
(Amounts in Thousands, except Per Share Data) March 31, 2024 March 31, 2023
Net Sales $ 1,284,352  100.0  % $ 1,327,288  100.0  %
Cost of Sales 1,180,833  91.9  % 1,220,804  92.0  %
Gross Profit 103,519  8.1  % 106,484  8.0  %
Selling and Administrative Expenses 50,736  4.0  % 50,204  3.8  %
Other General Expense (Income) (892) (0.1) % —  —  %
Restructuring Expense 1,622  0.1  % —  —  %
Goodwill Impairment 5,820  0.5  % —  —  %
Asset Impairment 16,564  1.3  % —  —  %
Operating Income 29,669  2.3  % 56,280  4.2  %
Interest Income 483  —  % 88  —  %
Interest Expense (17,459) (1.4) % (10,790) (0.8) %
Non-Operating Income (Expense), net (959) —  % 2,659  0.2  %
Other Income (Expense), net (17,935) (1.4) % (8,043) (0.6) %
Income Before Taxes on Income 11,734  0.9  % 48,237  3.6  %
Provision for Income Taxes (1,234) (0.1) % 11,608  0.8  %
Net Income $ 12,968  1.0  % $ 36,629  2.8  %
Earnings Per Share of Common Stock:
Basic $ 0.52  $ 1.47 
Diluted $ 0.51  $ 1.46 
Average Number of Shares Outstanding:
     Basic 25,084  24,868 
     Diluted 25,263  25,031 



Condensed Consolidated Statements of Cash Flows Nine Months Ended
(Unaudited) March 31,
(Amounts in Thousands) 2024 2023
Net Cash Flow provided by (used for) Operating Activities $ 24,717  $ (57,885)
Net Cash Flow used for Investing Activities (37,702) (66,497)
Net Cash Flow provided by Financing Activities 36,571  107,148 
Effect of Exchange Rate Change on Cash, Cash Equivalents, and Restricted Cash (113) (294)
Net Increase (Decrease) in Cash, Cash Equivalents, and Restricted Cash 23,473  (17,528)
Cash, Cash Equivalents, and Restricted Cash at Beginning of Period 43,864  49,851 
Cash, Cash Equivalents, and Restricted Cash at End of Period $ 67,337  $ 32,323 


(Unaudited)
Condensed Consolidated Balance Sheets March 31,
2024
June 30,
2023
(Amounts in Thousands)
ASSETS
    Cash and cash equivalents $ 65,208  $ 42,955 
    Receivables, net 277,894  308,167 
    Contract assets 76,073  78,798 
    Inventories 396,199  450,319 
    Prepaid expenses and other current assets 43,018  49,188 
    Assets held for sale 29,619  — 
    Property and Equipment, net 273,823  267,684 
    Goodwill 6,191  12,011 
    Other Intangible Assets, net 3,197  12,335 
    Other Assets 89,606  38,262 
        Total Assets $ 1,260,828  $ 1,259,719 
LIABILITIES AND SHARE OWNERS’ EQUITY
    Current portion of borrowings under credit facilities $ 84,618  $ 46,454 
    Accounts payable 248,174  322,274 
    Advances from customers 36,099  33,905 
    Accrued expenses 59,621  72,515 
    Liabilities held for sale 9,369  — 
    Long-term debt under credit facilities, less current portion 235,000  235,000 
    Long-term income taxes payable 3,255  5,859 
    Other long-term liabilities 45,631  19,718 
    Share Owners’ Equity 539,061  523,994 
        Total Liabilities and Share Owners’ Equity $ 1,260,828  $ 1,259,719 




Other Financial Metrics
(Unaudited)
(Amounts in Millions, except CCD)
At or For the
Three Months Ended Nine Months Ended
March 31, March 31,
2024 2023 2024 2023
Depreciation and Amortization $ 10.5  $ 8.2  $ 28.5  $ 23.8 
Stock-Based Compensation $ 1.8  $ 2.0  $ 5.4  $ 5.4 
Cash Conversion Days (CCD) (1)
110  92 
Open Orders (2)
$ 831  $ 882 
(1) Cash Conversion Days (“CCD”) are calculated as the sum of Days Sales Outstanding plus Contract Asset Days plus Production Days Supply on Hand less Accounts Payable Days and less Advances from Customers Days. CCD, or a similar metric, is used in our industry and by our management to measure the efficiency of managing working capital.
(2) Open Orders are the aggregate sales price of production pursuant to unfulfilled customer orders.

Select Financial Results of Automation, Test & Measurement
(Unaudited)
(Amounts in Millions)
Three Months Ended Nine Months Ended
March 31, March 31,
2024 2023 2024 2023
Net Sales $ 8.1  $ 16.8  $ 30.9  $ 40.6 
Operating Income (Loss) (1)
$ (25.4) $ 1.6  $ (24.3) $ 0.1 
(1) Includes goodwill impairment of $5.8 million and asset impairment of $16.6 million for the three and nine months ended March 31, 2024. Also includes allocated corporate overhead expenses.




Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Amounts in Thousands, except Per Share Data)
Three Months Ended Nine Months Ended
March 31, March 31,
2024 2023 2024 2023
Net Sales Growth (vs. same period in prior year) (12) % 32  % (3) % 36  %
Foreign Currency Exchange Impact —  % (2) % —  % (4) %
Constant Currency Growth (12) % 34  % (3) % 40  %
Selling and Administrative Expenses, as reported
$ 16,861  $ 17,752  $ 50,736  $ 50,204 
SERP
(277) (353) (584) (458)
Adjusted Selling and Administrative Expenses
$ 16,584  $ 17,399  $ 50,152  $ 49,746 
Operating Income (Loss), as reported
$ (6,431) $ 25,220  $ 29,669  $ 56,280 
SERP 277  353  584  458 
Legal Settlements (Recovery) (892) —  (892) — 
Restructuring Expense 1,622  —  1,622  — 
Goodwill Impairment 5,820  —  5,820  — 
Asset Impairment 16,564  —  16,564  — 
Adjusted Operating Income $ 16,960  $ 25,573  $ 53,367  $ 56,738 
Net Income (Loss), as reported
$ (6,076) $ 16,400  $ 12,968  $ 36,629 
Adjustments After Measurement Period on GES Acquisition —  —  —  279 
Legal Settlements (Recovery), After-Tax (676) —  (676) — 
Restructuring Expense, After-Tax 1,230  —  1,230  — 
Goodwill Impairment, After-Tax 4,414  —  4,414  — 
Asset Impairment, After-Tax 9,549  —  9,549  — 
Adjusted Net Income $ 8,441  $ 16,400  $ 27,485  $ 36,908 
Diluted Earnings per Share, as reported $ (0.24) $ 0.65  $ 0.51  $ 1.46 
Adjustments After Measurement Period on GES Acquisition —  —  —  0.01 
Legal Settlements (Recovery) (0.03) —  (0.03) — 
Restructuring Expense 0.05  —  0.05  — 
Goodwill Impairment 0.18  —  0.18  — 
Asset Impairment 0.38  —  0.38  — 
Adjusted Diluted Earnings per Share $ 0.34  $ 0.65  $ 1.09  $ 1.47 
Twelve Months Ended
March 31,
2024 2023
Operating Income $ 61,118  $ 76,858 
Goodwill Impairment 5,820  — 
SERP 827  (701)
Legal Recovery (1,104) — 
Restructuring Expense 1,622  — 
Asset Impairment 16,564  — 
Adjusted Operating Income (non-GAAP) $ 84,847  $ 76,157 
Tax Effect 19,947  20,375 
After-tax Adjusted Operating Income $ 64,900  $ 55,782 
Average Invested Capital (1)
$ 783,059  $ 659,911 
ROIC 8.3  % 8.5  %
(1) Average invested capital is computed using Share Owners’ equity plus current and non-current debt less cash and cash equivalents averaged for the last five quarters.